drugset / Trial / NCT00168818

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

NCT00168818 ↗

Phase 3 Completed 3494 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindPrevention

Summary

The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery.

Timeline

Start
2004-11
Primary completion
2006-07
Completion
—

Outcome

Met primary endpoint

paper Both doses were thus non-inferior to enoxaparin. PMID 17869635 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg —
Subject Dabigatran etexilate Unknown 220 mg —
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous